Literature DB >> 31545681

Effect of Transdermal Testosterone and Oral Progesterone on Drug-Induced QT Interval Lengthening in Older Men: A Randomized, Double-Blind, Placebo-Controlled Crossover-Design Study.

Elena Tomaselli Muensterman1, Heather A Jaynes1, Kevin M Sowinski1,2, Brian R Overholser1,2, Changyu Shen3, Richard J Kovacs4, James E Tisdale1,2.   

Abstract

Entities:  

Keywords:  abnormalities, drug-induced; electrocardiography; long QT syndrome; progesterone; testosterone

Mesh：

Substances：

Year:  2019        PMID： 31545681      PMCID： PMC6760325          DOI： 10.1161/CIRCULATIONAHA.119.041395

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  5 in total

1.  Cumulative experience of azimilide-associated torsades de pointes ventricular tachycardia in the 19 clinical studies comprising the azimilide database.

Authors:  Craig M Pratt; Hussein R Al-Khalidi; Jose M Brum; Michael J Holroyde; Peter J Schwartz; Stephen R Marcello; Martin Borggrefe; Paul Dorian; A John Camm
Journal:  J Am Coll Cardiol       Date:  2006-07-12       Impact factor: 24.094

Review 2.  Sex hormonal regulation of cardiac ion channels in drug-induced QT syndromes.

Authors:  Junko Kurokawa; Masami Kodama; Colleen E Clancy; Tetsushi Furukawa
Journal:  Pharmacol Ther       Date:  2016-09-04       Impact factor: 12.310

3.  Influence of Oral Progesterone Administration on Drug-Induced QT Interval Lengthening: A Randomized, Double-Blind, Placebo-Controlled Crossover Study.

Authors:  James E Tisdale; Heather A Jaynes; Brian R Overholser; Kevin M Sowinski; David A Flockhart; Richard J Kovacs
Journal:  JACC Clin Electrophysiol       Date:  2016-12

Review 4.  Torsade de pointes due to noncardiac drugs: most patients have easily identifiable risk factors.

Authors:  David Zeltser; Dan Justo; Amir Halkin; Vitaly Prokhorov; Karin Heller; Sami Viskin
Journal:  Medicine (Baltimore)       Date:  2003-07       Impact factor: 1.889

5.  Development and validation of a risk score to predict QT interval prolongation in hospitalized patients.

Authors:  James E Tisdale; Heather A Jaynes; Joanna R Kingery; Noha A Mourad; Tate N Trujillo; Brian R Overholser; Richard J Kovacs
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2013-05-28
  5 in total
  4 in total

1.  Testosterone use and shorter electrocardiographic QT interval duration in men living with and without HIV.

Authors:  P G Hiremath; F Bhondoekhan; S A Haberlen; H Ashikaga; F J Palella; G D'Souza; M J Budoff; L A Kingsley; A S Dobs; W S Post; E Z Soliman; T T Brown; K C Wu
Journal:  HIV Med       Date:  2020-12-03       Impact factor: 3.180

Review 2.  Sexual Dimorphisms, Anti-Hormonal Therapy and Cardiac Arrhythmias.

Authors:  Virginie Grouthier; Melissa Y Y Moey; Estelle Gandjbakhch; Xavier Waintraub; Christian Funck-Brentano; Anne Bachelot; Joe-Elie Salem
Journal:  Int J Mol Sci       Date:  2021-02-02       Impact factor: 5.923

Review 3.  Current National and International Guidelines for the Management of Male Hypogonadism: Helping Clinicians to Navigate Variation in Diagnostic Criteria and Treatment Recommendations.

Authors:  Ahmed Al-Sharefi; Richard Quinton
Journal:  Endocrinol Metab (Seoul)       Date:  2020-09-22

Review 4.  Cardiovascular risk and testosterone - from subclinical atherosclerosis to lipoprotein function to heart failure.

Authors:  Baris Gencer; Marco Bonomi; Maria Pia Adorni; Cesare R Sirtori; François Mach; Massimiliano Ruscica
Journal:  Rev Endocr Metab Disord       Date:  2021-02-22       Impact factor: 6.514
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.